Kamada
Kamada's revenue rose 12.1% to $180 million in fiscal 2025. Its operating margin was 14.5%, up from 12.5% a year earlier. Free cash flow was $16 million, down 57.5%. It paid out $12 million in dividends and buybacks, 74% of free cash flow. The diluted share count rose 0.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
Income statement
From fiscal 2017 to 2025, earnings per share grew 8.7% a year and net income 14.4% a year, as new shares raised the share count by 53% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | 34 | 56 | 78 | 76 |
| Debt incl. finance leases | 23 | 26 | — | — | — |
| Net debt (negative means net cash) | — | −8 | — | — | — |
| Net debt to EBITDA | — | −1.4x | — | — | — |
| Debt to equity | 0.1x | 0.1x | — | — | — |
| Interest coverage | −2.5x | 5.0x | 7.8x | 30.4x | 30.4x |
| Current ratio | 2.4x | 1.8x | 3.4x | 3.7x | 4.1x |
| Quick ratio | 1.2x | 0.9x | 1.6x | 2.1x | 2.3x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | 9.1% | 35.8% | 20.8% |
| Altman Z'' | 4.36 | 4.93 | 5.42 |
| Accruals ratio | 1.2% | −9.1% | −1.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Kamada side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kamada | FY25 | 12.1% | 14.5% | 8.7% | — | — | — | |
| Glass House Brands | FY25 | −9.4% | −9.1% | −8.6% | −10.0% | — | 3 | Compare |
| Stoke Therapeutics | FY25 | 404.5% | −11.2% | 24.4% | — | — | — | Compare |
| Phathom Pharmaceuticals | FY25 | 216.9% | −91.4% | −95.4% | — | — | 4 | Compare |
| Syndax Pharmaceuticals | FY25 | 627.8% | −158.4% | −187.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 78 | 103 | 114 | 127 | 133 | 104 | 129 | 142 | 161 | 180 |
| Revenue growth | 10.8% | 32.7% | 11.3% | 11.1% | 4.8% | −22.2% | 24.8% | 10.2% | 12.9% | 12.1% |
| Gross profit | 21 | 32 | 42 | 50 | 48 | 30 | 47 | 56 | 70 | 76 |
| Research and development | 16 | 12 | 10 | 13 | 14 | 11 | 13 | 14 | 15 | 13 |
| Operating income | −6 | 7 | 19 | 23 | 19 | −1 | 4 | 10 | 20 | 26 |
| Net income | −7 | 7 | 22 | 22 | 17 | −2 | −2 | 8 | 14 | 20 |
| Diluted EPS (US$) | −0.18 | 0.18 | 0.55 | 0.55 | 0.38 | −0.05 | −0.05 | 0.15 | 0.25 | 0.35 |
| Diluted shares (millions) | 36 | 38 | 40 | 41 | 45 | 45 | 45 | 54 | 58 | 58 |
| Cash flow | ||||||||||
| Cash from operations | 2 | 4 | 10 | 28 | 19 | −9 | 29 | 4 | 48 | 26 |
| Capital expenditure | 3 | 4 | 3 | 2 | 6 | 4 | 4 | 6 | 11 | 10 |
| Free cash flow | −1 | −1 | 8 | 25 | 14 | −13 | 25 | −2 | 37 | 16 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 10 | 13 | 18 | 74 | 109 | — | 34 | 56 | 78 | 76 |
| Debt incl. finance leases | 2 | 3 | 1 | 1 | 0 | 23 | 26 | — | — | — |
| Total assets | 100 | 122 | 138 | 174 | 211 | 319 | 322 | 355 | 372 | 379 |
| Total liabilities | 33 | 33 | 26 | 38 | 32 | 142 | 146 | 111 | 113 | 110 |
| Shareholders' equity | 67 | 90 | 112 | 135 | 179 | 177 | 176 | 244 | 260 | 269 |
| Margins and ratios | ||||||||||
| Gross margin | 27.6% | 31.2% | 36.2% | 39.1% | 35.7% | 29.3% | 36.1% | 38.9% | 43.5% | 42.3% |
| Operating margin | −7.1% | 7.2% | 16.8% | 17.9% | 14.4% | −0.7% | 3.5% | 7.1% | 12.5% | 14.5% |
| Net margin | −8.7% | 6.7% | 19.5% | 17.5% | 12.9% | −2.1% | −1.8% | 5.8% | 9.0% | 11.2% |
| Free cash flow margin | −1.0% | −0.5% | 6.7% | 19.9% | 10.2% | −12.1% | 19.2% | −1.1% | 22.9% | 8.7% |
| Rule of 40 (growth + FCF margin) | 9.9% | 32.1% | 18.0% | 31.0% | 15.0% | −34.3% | 44.0% | 9.1% | 35.8% | 20.8% |
| Return on capital | — | 10.4% | 22.0% | 27.9% | 26.8% | — | — | — | — | — |
| Return on equity | — | 8.8% | 22.1% | 18.0% | 10.9% | −1.2% | −1.3% | 3.9% | 5.7% | 7.6% |
| Return on assets | — | 6.2% | 17.1% | 14.3% | 8.9% | −0.8% | −0.7% | 2.5% | 4.0% | 5.4% |
| Net debt to EBITDA | — | −1.0x | −0.8x | −2.8x | −4.8x | — | −1.4x | — | — | — |